Introduction:
AMPLY Discovery Ltd, a techbio company based in Belfast, has secured £1.4m in grant funding to further develop its AI-based drug discovery platform. The funding will be used to support the company’s research and development efforts in tackling complex diseases such as cancer, metabolic disorders, and infectious diseases.
- AMPLY Discovery Ltd is utilizing AI and synthetic biology to accelerate the discovery of drug candidates for various diseases.
- The company’s technology platform has been under development for more than a decade.
- AMPLY is currently focused on two flagship R&D programs: one aimed at developing RNAi therapies for genetically mediated cancers and another focused on developing inhaled antimicrobial therapies to combat multi-drug resistant lung infections.
- The company plans to raise an additional £1.4m in seed funding in the second quarter of 2024.
- The new grant funding highlights the progress AMPLY is making in building an efficient platform for drug discovery.
Conclusion:
AMPLY Discovery Ltd has secured £1.4m in funding to advance its AI-based drug discovery platform, which aims to tackle complex diseases such as cancer and infectious diseases. The company’s technology platform, developed over a decade, is being used in two flagship R&D programs to develop RNAi therapies for genetically mediated cancers and antimicrobial therapies for multi-drug resistant lung infections. The additional funding will further support the company in its mission to revolutionize the drug discovery process.
